{"nctId":"NCT03398148","briefTitle":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis","startDateStruct":{"date":"2018-03-07","type":"ACTUAL"},"conditions":["Ulcerative Colitis (UC)"],"count":1558,"armGroups":[{"label":"Substudy 1, Induction Period 1: Double-blind Placebo IV","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo for risankizumab"]},{"label":"Substudy 1, Induction Period 1: Double-blind Risankizumab 600mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 1, Induction Period 1: Double-blind Risankizumab 1200mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 1, Induction Period 1: Double-blind Risankizumab 1800mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 1, Induction Period 1: Open-label Risankizumab 1800mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 180mg SC","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab SC"]},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 360mg SC","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab SC"]},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 1, Induction Period 2: Double-blind Risankizumab 1800mg IV Pbo","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 2, Induction Period 1: Double-blind Placebo IV","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: placebo for risankizumab"]},{"label":"Substudy 2, Induction Period 1: Double-blind Risankizumab 1200mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 180mg SC","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab SC"]},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 360mg SC","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab SC"]},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]},{"label":"Substudy 2, Induction Period 2: Double-blind Risankizumab 1200mg IV Pbo","type":"EXPERIMENTAL","interventionNames":["Drug: risankizumab IV"]}],"interventions":[{"name":"risankizumab IV","otherNames":["ABBV-066","BI 655066"]},{"name":"placebo for risankizumab","otherNames":[]},{"name":"risankizumab SC","otherNames":["ABBV-066","BI 655066"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female aged \\>=18 to \\<= 80 years at the Baseline Visit. Where locally permissible, subjects 16 to \\< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit.\n* Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to Baseline.\n* Active UC as assessed by Adapted Mayo Score and Endoscopic Subscore.\n* Demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies.\n* Females must be postmenopausal for more than 1 year or surgically sterile or practicing specific forms of birth control.\n\nExclusion Criteria:\n\n* Participant with a current diagnosis of Crohn's disease (CD), inflammatory bowel disease-unclassified (IBD-U) or a history of radiation colitis or ischemic colitis.\n* Participant receiving prohibited medications and treatment.\n* Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy.\n* Participant with currently known complications of UC (e.g., megacolon).\n* No known active Coronavirus Disease - 2019 (COVID-19) infection.","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"80 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Sub-Study 1, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"6","spread":null},{"groupId":"OG003","value":"6","spread":null},{"groupId":"OG004","value":"42","spread":null}]}]}]},{"type":"PRIMARY","title":"Sub-Study 2: Percentage of Participants Achieving Clinical Remission Per Adapted Mayo Score","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)\n\nThe overall Adapted Mayo score ranges from 0 to 9 where higher scores represent more severe disease.\n\nFor Sub-Study 2, clinical remission was defined as SFS ≤ 1, and not greater than baseline, RBS of 0, and endoscopic subscore ≤ 1. Evidence of friability during endoscopy in subjects with otherwise \"mild\" endoscopic activity will confer an endoscopic subscore of 2.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.2","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Achieving Endoscopic Improvement","description":"Endoscopic improvement is defined as endoscopy subscore of 0 or 1.\n\nEndoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"15","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"9","spread":null},{"groupId":"OG004","value":"61","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Achieving Clinical Remission Per Full Mayo Score in Participants With a Full Mayo Score of 6 to 12 at Baseline","description":"The Mayo score is a tool designed to measure disease activity for ulcerative colitis. The Full Mayo score (FMS) ranges from 0 (normal or inactive disease) to 12 (severe disease) and is calculated as the sum of 4 subscores (stool frequency, rectal bleeding, endoscopy \\[confirmed by a central reader\\], and physician's global assessment), each of which ranges from 0 (normal) to 3 (severe disease). Negative changes indicate improvement.\n\nClinical remission per FMS is defined as Mayo Score ≤ 2 and no individual subscore \\> 1.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)\n\nThe overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease.\n\nClinical response per Adapted Mayo Score was defined as decrease from baseline in Adapted Mayo Score ≥ 2 points and ≥ 30%, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"31","spread":null},{"groupId":"OG004","value":"157","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score","description":"Clinical response per Partial Adapted Mayo Score (without endoscopy).\n\nThe Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n\nThe overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease.\n\nClinical response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo score \\>= 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"20","spread":null},{"groupId":"OG002","value":"28","spread":null},{"groupId":"OG003","value":"22","spread":null},{"groupId":"OG004","value":"148","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Achieving Endoscopic Remission","description":"Endoscopic remission was defined as endoscopy subscore of 0.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"3","spread":null},{"groupId":"OG003","value":"5","spread":null},{"groupId":"OG004","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants With Hospitalization","description":"Participants with an event that results in admission to the hospital.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"4","spread":null},{"groupId":"OG003","value":"3","spread":null},{"groupId":"OG004","value":"19","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR)","description":"Mucosal healing defined as endoscopic and histologic remission.\n\nMucosal healing is defined as an endoscopic score of 0 and Geboes score \\< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"2","spread":null},{"groupId":"OG003","value":"1","spread":null},{"groupId":"OG004","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Change in Ulcerative Colitis Symptom Questionnaire (UC-SQ)","description":"The US-SQ is a patient questionnaire to assess severity of Ulcerative Colitis (UC) related gastrointestinal symptoms (e.g., frequent bowel movements, abdominal pain, cramping) and non-gastrointestinal symptoms (e.g., joint pain and sleep difficulties).\n\nIt consists of 17 questions and each question is answered on a scale from can be answered on a scale from 1 (Not at all/ never) to 5 (Very much/Always) with overall symptom score range from 17 to 85. A lower score indicates lower UC severity.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","spread":"1.53"},{"groupId":"OG001","value":"-13.8","spread":"1.50"},{"groupId":"OG002","value":"-15.6","spread":"1.46"},{"groupId":"OG003","value":"-15.1","spread":"1.51"},{"groupId":"OG004","value":"-17.1","spread":"0.58"}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Change in Inflammatory Bowel Disease Questionnaire (IBDQ)","description":"The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.\n\nThe IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).\n\nThe IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.1","spread":"4.67"},{"groupId":"OG001","value":"37.4","spread":"4.56"},{"groupId":"OG002","value":"40.3","spread":"4.38"},{"groupId":"OG003","value":"40.0","spread":"4.55"},{"groupId":"OG004","value":"49.5","spread":"1.86"}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Physical Component","description":"The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \\[MCS\\] and physical \\[PCS\\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.904","spread":"0.8907"},{"groupId":"OG001","value":"5.112","spread":"0.8751"},{"groupId":"OG002","value":"6.350","spread":"0.8341"},{"groupId":"OG003","value":"6.296","spread":"0.8675"},{"groupId":"OG004","value":"7.719","spread":"0.3929"}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Change From Baseline in Short Form-36 (SF-36) - Mental Component","description":"The SF-36 (Version 2) is a self-administered, health-related survey that measures the impact of disease on overall quality of life during the past 4 weeks. SF-36 consists of 36 questions covering 8 health domains: physical functioning, bodily pain, role limitations due to physical problems and emotional problems, general health, mental health, social functioning, vitality, and 2 component scores (mental \\[MCS\\] and physical \\[PCS\\]). MCS consisted of social functioning, vitality, mental health, and role-emotional scales. PCS consisted of physical functioning, bodily pain, role-physical, and general health scales. Each domain is scored by summing the individual items and transforming the scores into a 0 (poorest health) to 100 (best health) scale with higher scores indicating better health status or functioning.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.094","spread":"1.2533"},{"groupId":"OG001","value":"6.756","spread":"1.2319"},{"groupId":"OG002","value":"7.284","spread":"1.1739"},{"groupId":"OG003","value":"5.442","spread":"1.2185"},{"groupId":"OG004","value":"7.777","spread":"0.4777"}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)","description":"The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale.\n\n0 = not at all\n\n1. = a little bit\n2. = somewhat\n3. = quite a bit\n4. = very much\n\nThe FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":"1.37"},{"groupId":"OG001","value":"7.6","spread":"1.35"},{"groupId":"OG002","value":"9.0","spread":"1.29"},{"groupId":"OG003","value":"8.3","spread":"1.33"},{"groupId":"OG004","value":"10.7","spread":"0.54"}]}]}]},{"type":"SECONDARY","title":"Sub-Study 1: Percentage of Participants Undergoing Ulcerative Colitis (UC)-Related Surgeries","description":"Participants who underwent surgery related to UC.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"0","spread":null},{"groupId":"OG003","value":"0","spread":null},{"groupId":"OG004","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Adapted Mayo Score","description":"The Adapted Mayo Score is a composite score of UC disease activity based on the following 3 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n3. Endoscopic subscore, scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)\n\nThe overall Adapted Mayo Score ranges from 0 to 9 where higher scores represent more severe disease.\n\nClinical Response is defined as a decrease from baseline in the Adapted Mayo Score ≥ 2 points and ≥ 30% from baseline, and a decrease in RBS ≥ 1 or an absolute RBS ≤ 1).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"64.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving Endoscopic Improvement","description":"Endoscopic Improvement is defined as an endoscopic subscore of 0 or 1.\n\nEndoscopies were assessed by a blinded central reader and scored according to the following scale: 0 = Normal or inactive disease; 1 = Mild disease (erythema, decreased vascular pattern); 2 = Moderate disease (marked erythema, lack of vascular pattern, any friability, erosions); 3 = Severe disease (spontaneous bleeding, ulceration).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"36.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Improvement (HEMI)","description":"Histologic-Endoscopic Mucosal Improvement is defined as an endoscopic subscore of 0 or 1 without evidence of friability and a Geboes score ≤ 3.1.\n\nThe endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers).\n\nThe Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.7","spread":null},{"groupId":"OG001","value":"24.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving Endoscopic Remission","description":"Endoscopic remission per endoscopy subscore.\n\nEndoscopic Remission: endoscopic subscore = 0.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"10.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving Clinical Response Per Partial Adapted Mayo Score at Week 4","description":"Clinical response per Partial Adapted Mayo Score (without endoscopy).\n\nThe Partial Mayo Score is a composite score of UC disease activity based on the following 2 subscores:\n\n1. Stool frequency subscore (SFS), scored from 0 (normal number of stools) to 3 (5 or more stools more than normal)\n2. Rectal bleeding subscore (RBS), scored from 0 (no blood seen) to 3 (blood alone passed)\n\nThe overall Partial Mayo Score ranges from 0 to 6 with higher scores representing more severe disease.\n\nClinical Response per Partial Mayo Score is defined as a decrease in Partial Adapted Mayo Score ≥ 1 points and ≥ 30% from Baseline, plus a decrease in RBS ≥ 1 or an absolute RBS ≤ 1.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.5","spread":null},{"groupId":"OG001","value":"52.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving No Bowel Urgency","description":"Percentage of participants who reported no bowel urgency. Bowel urgency was assessed by participants in a subject diary completed once a day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"44.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving No Abdominal Pain","description":"Percentage of participants who reported no abdominal pain. Abdominal pain was assessed by participants in a subject diary completed once a day.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.5","spread":null},{"groupId":"OG001","value":"35.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving Histologic Endoscopic Mucosal Remission (HEMR): Endoscopy Subscore of 0 and Geboes Score < 2.0) at Week 12","description":"Mucosal healing defined as endoscopic and histologic remission.\n\nMucosal healing is defined as an endoscopic score of 0 and Geboes score \\< 2.0. The endoscopic subscore ranges from 0 (normal or inactive disease) to 3 (severe disease with spontaneous bleeding, ulceration).\n\nThe Geboes histologic index includes seven histological features (architectural change, chronic inflammatory infiltrate, lamina propria neutrophils and eosinophils, neutrophils in epithelium, crypt destruction and erosion or ulcers). The Geboes score has 6 grades, each with 3-5 subgrades: Grade 0, structural change only; Grade 1, chronic inflammation; Grade 2, lamina propria neutrophils and eosinophils; Grade 3, neutrophils in epithelium; Grade 4, crypt destruction; and Grade 5, erosions or ulceration.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)","description":"The FACIT-Fatigue Scale is a validated self-administered 13-item tool that measures an individual's level of fatigue during their usual daily activities over the past 7 days. Each of the fatigue and impact of fatigue items are measured on a four-point Likert scale.\n\n0 = not at all\n\n1. = a little bit\n2. = somewhat\n3. = quite a bit\n4. = very much\n\nThe FACIT Fatigue Scale is the sum of the individual 13 scores and ranges from 0 to 52 where higher scores indicate better the quality of life. A positive change from baseline indicates improvement.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"7.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Change in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score","description":"The IBDQ is used to assess the quality of life of patients with inflammatory bowel disease.\n\nThe IBDQ is a 32-item (ranges 1 - 7) self-report questionnaire for patients with IBD to evaluate the patient reported outcomes across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms (fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), and emotional function (anger, depression, irritability).\n\nThe IBDQ total Score ranges from 32 to 224 with a higher score indicating better outcome.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.3","spread":null},{"groupId":"OG001","value":"42.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Occurrence of UC-related Hospitalizations","description":"Participants with an UC-related event that results in admission to the hospital.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"0.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving No Nocturnal Bowel Movements","description":"Percentage of participants who reported no nocturnal bowel movements.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"67.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Percentage of Participants Achieving No Tenesmus","description":"Percentage of participants who reported no tenesmus.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.2","spread":null},{"groupId":"OG001","value":"48.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Change in Number of Fecal Incontinence Episodes Per Week","description":"Change in number of fecal incontinence episodes per week.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.213","spread":null},{"groupId":"OG001","value":"-3.839","spread":null}]}]}]},{"type":"SECONDARY","title":"Sub-Study 2: Change in Number of Days Per Week With Sleep Interrupted Due to UC Symptoms","description":"Change from baseline in number of days per week with sleep interrupted due to UC symptoms.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.505","spread":null},{"groupId":"OG001","value":"-2.485","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":59},"commonTop":["NASOPHARYNGITIS","HEADACHE","ANAEMIA","COVID-19","COLITIS ULCERATIVE"]}}}